Matthew Truesdale, MD, FACS, discusses validation data showing that IsoPSA improves risk stratification for clinically significant prostate cancer in men with elevated PSA both with and without ...
FDA cleared Titan Prime, a next-generation IPP, emphasizing improved flaccid flexibility intended to enhance comfort and concealability for erectile dysfunction patients. Approval of generic Ga-68 ...
Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer. Punnen explained that the ...
CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1–6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...
Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.
Tentative FDA approval enables Lupin to prepare for commercial launch of generic enzalutamide once remaining exclusivity and patent constraints no longer block approval. Bioequivalence was established ...
Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...
In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. Jonathan ...
"We knew that the MS or momentary squeeze pump, originally designed at AMS was a fine device, but it did have some issues. We thought we could make it even better," says Ronald A. Morton, MD. The ...
Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...
Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue. Loeb explained that her interest in this work was sparked by a study published ...
Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results